275 related articles for article (PubMed ID: 16410826)
1. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
Nemunaitis J; Sterman D; Jablons D; Smith JW; Fox B; Maples P; Hamilton S; Borellini F; Lin A; Morali S; Hege K
J Natl Cancer Inst; 2004 Feb; 96(4):326-31. PubMed ID: 14970281
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
[TBL] [Abstract][Full Text] [Related]
4. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
Salgia R; Lynch T; Skarin A; Lucca J; Lynch C; Jung K; Hodi FS; Jaklitsch M; Mentzer S; Swanson S; Lukanich J; Bueno R; Wain J; Mathisen D; Wright C; Fidias P; Donahue D; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Sugarbaker D; Mihm M; Dranoff G
J Clin Oncol; 2003 Feb; 21(4):624-30. PubMed ID: 12586798
[TBL] [Abstract][Full Text] [Related]
6. Vaccines in cancer: GVAX, a GM-CSF gene vaccine.
Nemunaitis J
Expert Rev Vaccines; 2005 Jun; 4(3):259-74. PubMed ID: 16026242
[TBL] [Abstract][Full Text] [Related]
7. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus[correction to fcous] on non-small-cell lung cancer.
Nemunaitis J; Nemunaitis J
Clin Lung Cancer; 2003 Nov; 5(3):148-57. PubMed ID: 14667270
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
10. GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer.
Nemunaitis J
J Control Release; 2003 Aug; 91(1-2):225-31. PubMed ID: 12932654
[TBL] [Abstract][Full Text] [Related]
11. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation.
Jaffee EM; Hruban RH; Biedrzycki B; Laheru D; Schepers K; Sauter PR; Goemann M; Coleman J; Grochow L; Donehower RC; Lillemoe KD; O'Reilly S; Abrams RA; Pardoll DM; Cameron JL; Yeo CJ
J Clin Oncol; 2001 Jan; 19(1):145-56. PubMed ID: 11134207
[TBL] [Abstract][Full Text] [Related]
12. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma.
Mahvi DM; Sondel PM; Yang NS; Albertini MR; Schiller JH; Hank J; Heiner J; Gan J; Swain W; Logrono R
Hum Gene Ther; 1997 May; 8(7):875-91. PubMed ID: 9143914
[TBL] [Abstract][Full Text] [Related]
13. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
14. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
15. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine.
Thomas MC; Greten TF; Pardoll DM; Jaffee EM
Hum Gene Ther; 1998 Apr; 9(6):835-43. PubMed ID: 9581906
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine.
Olivares J; Kumar P; Yu Y; Maples PB; Senzer N; Bedell C; Barve M; Tong A; Pappen BO; Kuhn J; Magee M; Wallraven G; Nemunaitis J
Clin Cancer Res; 2011 Jan; 17(1):183-92. PubMed ID: 21208907
[TBL] [Abstract][Full Text] [Related]
17. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
18. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
Hege KM; Jooss K; Pardoll D
Int Rev Immunol; 2006; 25(5-6):321-52. PubMed ID: 17169779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]